Psyence Biomedical Ltd.PBM
Price (close)
$5.86
Market cap
$22.4M
P/E
22.1x
Revenue (FY)
—
Net income
$1.0M
Dividend yield
—
1-year total return
-95.1%
Net margin
—
Revenue growth
—
Debt / equity
—
What Psyence Biomedical Ltd. does.
vertically integrated biopharmaceutical company focused on psychedelic-based therapeutics, with pharmaceutical-grade drug candidates manufactured
through its investment in PsyLabs. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic)
psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs and
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$3.2M | -$51.2M | $1.0M |
| Free cash flow | — | — | -$3.0M | -$3.7M |
More on PBM.
- Psyence Biomedical Ltd. summary
- Psyence Biomedical Ltd. financial statements
- Psyence Biomedical Ltd. key metrics
- Psyence Biomedical Ltd. health scores and style box
- Psyence Biomedical Ltd. earnings
- Psyence Biomedical Ltd. dividends
- Psyence Biomedical Ltd. valuation
- Psyence Biomedical Ltd. ownership and insiders
- Psyence Biomedical Ltd. peers
Figures from Psyence Biomedical Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.